Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.34)
# 4,332
Out of 5,154 analysts
35
Total ratings
18.75%
Success rate
-30.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $55 | $18.97 | +189.93% | 4 | May 14, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $26.54 | - | 12 | Mar 12, 2025 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $114.33 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $13.44 | +383.63% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $1.82 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $2.00 | +600.00% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $56.50 | +89.38% | 4 | Aug 8, 2022 |
Legend Biotech
May 14, 2025
Reiterates: Overweight
Price Target: $55
Current: $18.97
Upside: +189.93%
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.54
Upside: -
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $114.33
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $13.44
Upside: +383.63%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.82
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.00
Upside: +600.00%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $56.50
Upside: +89.38%